Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus radiochemotherapy as neoadjuvant treatment for triple-negative breast cancer
ChiCTR2600128105Phase 2Recruiting
- Sponsor
- Changde First People's Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706 in triple-negative breast cancer (TNBC) (3 cohorts), sponsored by Changde First People's Hospital. Primary endpoint: Total pathological complete response rate. Started Jul 2026; status: recruiting.
02
Drugs
QL1706
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600128105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128105.